Tirzepatide for weight loss in MRD-positive early breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests whether the weight-loss drug tirzepatide (Mounjaro) can help prevent breast cancer from coming back in people who are overweight and have a sign of leftover cancer cells in their blood (called MRD-positive). You must have already finished at least one year of hormone therapy for early-stage breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You were diagnosed with hormone receptor-positive, HER2-negative breast cancer that spread to lymph nodes in the past 15 years
- You are overweight or obese (BMI over 27)
- You have had a positive blood test for minimal residual disease (MRD) after completing at least 1 year of hormone therapy
- You have not used insulin for diabetes, and have not taken a GLP-1 weight-loss drug in the last 3 months
- You have no evidence of cancer spread (metastasis) on recent scans or blood work
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if tirzepatide, a weight-loss medication, can help postmenopausal women with hormone-positive breast cancer who have obesity. It aims to improve health outcomes after completing cancer treatment.
This study tests if tirzepatide (a weight loss drug) can help women and men with early-stage hormone receptor-positive breast cancer who are overweight or obese. The goal is to see if losing weight can improve outcomes after completing their initial breast cancer treatment.
This study tests whether a weight-loss medication can affect breast cancer tumors before surgery. It is for postmenopausal women with early-stage, hormone-positive breast cancer who are overweight or obese.
This trial tests the weight‑loss medication tirzepatide (Mounjaro) in people who are overweight or have obesity and have stable coronary artery disease. The goal is to see if tirzepatide can reduce dangerous fatty plaque in heart arteries.
This trial tests if the weight-loss drug tirzepatide can help people with obesity-related endometrial cancer before their hysterectomy. It may improve surgical outcomes and overall health.
This trial tests whether tirzepatide, a weekly injection that helps with weight loss and blood sugar control, can improve outcomes for women with obesity and early-stage endometrial cancer (or precancerous changes) who are scheduled for surgery. The goal is to see if taking this medication before surgery can help shrink the cancer or improve surgical results.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.